A US judge has unsealed records from a Kentucky lawsuit against the maker of the prescription painkiller OxyContin, including the secret testimony of a former company president.
Judge Steven Combs ordered the records be released in 32 days but agreed to delay the order if Purdue Pharma appeals.
OxyContin is a powerfully addictive prescription painkiller that was marketed for its ability to slowly release its effects over a 12 hour period.
The company suggested this long-acting formula made it less addictive and safer for patients but users quickly found the pill lost its time-release qualities if it was crushed, resulting in an instant high.
In 2006, the company agreed to plead guilty and pay more than $US630 million ($A853 million) to settle federal charges that it misled doctors and patients about the risks of its top-selling drug.
The company released a new version of the drug in 2010 that they said deters abuse.
Kentucky was particularly affected by the drug, as it was prescribed to many injured coal miners in the eastern part of the state.
In 2007, Kentucky's attorney general filed a separate lawsuit against Purdue Pharma. Both sides settled the case in December and the company agreed to pay Kentucky $US24 million.
But the lawsuit generated more than 17 million pages of documents, including marketing strategies, training manuals, instructions to sales representatives and testimony from company officials.
The records include a deposition of Dr Richard Sackler, a former Purdue Pharma president and a member of the family that controls the company.
The judge in the case agreed to seal any records Purdue Pharma marked as confidential.
But Statnews.com, a health news website owned by Boston Globe owner John W. Henry, sued to have the records released once the case was resolved.
They are particularly interested in Sackler's testimony, as it could reveal how much the company knew about how addictive OxyContin truly is.
Lawyers for Purdue Pharma said the company agreed to hand over documents and give Kentucky's lawyers access to high level company officials because it believed the documents would never be made public. They argued that releasing the documents now would betray that trust and bog down the state's civil court docket.
OxyContin had global sales of $US2.5 billion in 2014, more than any other prescription painkiller.
Richard Silbert, the company's chief litigation counsel, confirmed it would appeal the judge's decision but declined to further comment.
Share
